Macluumaad dheeraad ah ― Somali

Laysarka Q-switched Nd:YAG waxaa loo yaqaanaa inuu si wax ku ool ah u daweeyo nevus of Ota iyo xaaladaha la midka ah. Waxaan sameynay daraasad si aan u aragno sida ugu wanaagsan ee high-fluence 1064 nm Q-switched Nd:YAG laser uu uga shaqeeyay dhibco Mongoliyaan ah oo ku yaal meelo aan caadi ahayn, iyada oo aan sababin in maqaarku iftiimiyo. Waxaan barannay 61 bukaan oo leh dhibcoas, annagoo baaraynay wadar ahaan 70 nabar. Kala badh nabarrada ayaa lagu daweeyay laysarka, halka kuwa kalena aan la daweyn marka la barbardhigo. Waxaan ku qiimeynay natiijooyinka anagoo adeegsanayna cabir iyo aalad lagu magacaabo Mexameter® si aan u cabbirno heerarka melanin. Bukaannada ayaa la raacay celcelis ahaan 14 bilood kooxda daawaynta iyo 18 bilood ee kooxda daawaynta. Dhammaadkii daraasadda, waxaan helnay kala duwanaansho weyn oo ku saabsan dhibcaha miisaanka iyo heerarka melanin ee u dhexeeya kooxaha la daaweeyay iyo kuwa aan la daweyn, iyadoo kooxda la daaweeyay laser ay muujisay natiijooyin wanaagsan. Laysarka high-fluence Q-switched Nd:YAG , isaga oo aan keenin iftiin maqaarka ah, wuxuu cadeeyay waxtar iyo badbaado loogu talagalay daawaynta dhibcaha Mongoliyaanka aan caadiga ahayn.
The Q-switched Nd:YAG laser is known to effectively treat nevus of Ota and similar conditions. We conducted a study to see how well a high-fluence 1064 nm Q-switched Nd:YAG laser worked on Mongolian spots in unusual areas, without causing the skin to lighten. We studied 61 patients with these spots, examining a total of 70 lesions. Half of lesions were treated with the laser, while others were left untreated for comparison. We evaluated the results using a scale and a device called a Mexameter® to measure melanin levels. Patients were followed up for an average of 14 months in the treatment group and 18 months in the observation group. At the end of the study, we found significant differences in the scale scores and melanin levels between the treated and untreated groups, with the laser-treated group showing better outcomes. The high-fluence Q-switched Nd:YAG laser, without causing skin lightening, proved effective and safe for treating these unusual Mongolian spots.

Waxaan barannay waxtarka iyo badbaadada isticmaalka daawaynta laser gaarka ah ee ABNOM , waxaanan eegnay arrimaha saameynaya sida ugu wanaagsan ee ay u shaqeyso. Waxaan eegnay 110 bukaan oo lahaa ABNOM oo helay inta u dhaxaysa laba ilaa sagaal daawaynta laysarka. Waxaan ogaanay in daawadu ay si ka wanaagsan u shaqeysay intii lagu jiray muddada dheer ee la sameeyay, laakiin aan si fiican u fiicnayn bukaannada da'da weyn. Waxa kale oo ay si fiican uga shaqeysay bukaanada leh maqaarka khafiifka ah (nooca III) iyo meelaha yar yar ee ay saameeyeen (in ka yar 10 cm2) . Melasma oo ay weheliso ABNOM waxay daawaynta ka dhigtay mid aan waxtar lahayn. Midabka ama tirada meelaha ay saamaysay uma eka inay wax isbeddel ah sameeyeen. Qiyaastii 10% bukaannada ayaa yeeshay dhibco madow daawaynta ka dib. Daawaynta badan ee hore waxay keentay natiijooyin wanaagsan. Bukaannada da'da ah ee leh maqaarka madow iyo dhibco madow waxay u badan tahay inay yeeshaan dhibco madow daawaynta ka dib. Bukaanka qaba ABNOM iyo melasma, waxa u fiican in la isticmaalo leysarka tamarta hoose si looga fogaado in melasma ay ka sii darto.
To evaluate the efficacy and safety of 1064-nm Q-switched Nd:YAG laser (QSNYL) therapy for ABNOM and to identify the factors influencing the outcome. A total of 110 patients with ABNOM were retrospectively evaluated and received two-to-nine treatment sessions. The curative effect was positively correlated with the treatment time and negatively correlated with the increasing age at first treatment (p < 0.05). The curative effect was better in patients with skin type III than those with type IV ( p < 0.05) and in patients with a lesion area of less than 10 cm2 than those with a larger affected area (p < 0.05). Additionally, the treatment effect was poorer in patients with concomitant melasma (p < 0.05). The treatment effect was not significantly correlated with the lesion color or number of affected sites (p > 0.05). Eleven patients (10%) developed postinflammatory hyperpigmentation (PIH). Early and repeated QSNYL therapy achieved satisfactory results for ABNOM. The risk of PIH after laser treatment is highest among patients with older age, darker lesion color, and darker skin color. For patients with ABNOM with concurrent melasma, low-energy laser therapy is recommended to reduce the risk of melasma aggravation.